

PRESSURE BIOSCIENCES INC.

14 Norfolk Avenue
South Easton, MA 02375
(T) 508-230-1828
(F) 508-230-1829
info@pressurebiosciences.com

Mr. Richard T. Schumacher, CEO, President
Dr. Edmund Y. Ting, SVP of Engineering
Dr. Nathan P. Lawrence, Vice President of M&S
Dr. Alexander V. Lazarev, Vice President of R&D
Mr. Joseph L. Damasio Jr, VP of Finance and CFO

STOCK OVERVIEW

Symbol:	PBIO	Recent Close:	\$3.74 (as of 09/14/18)
Exchange:	OTCQB	52-Week Range:	\$0.70 - \$5.00
Shares OS ¹ :	1.5M (7.2M FD)	Market Capitalization ² :	\$5.6M (\$26.9M FD)
Float:	~1.4M	Fiscal Year End:	December 31
Revenue (FY2017):	\$2.24M	Transfer Agent:	Computershare

COMPANY OVERVIEW

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. Our products/services are based on three patented, pressure-enhanced platforms: (i) Pressure Cycling Technology (“PCT”), (ii) Pressure Enabled Protein Manufacturing Technology (“PreEMT”), and (iii) Ultra Shear Technology (“UST”).

The PCT Platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction). Our primary focus is in making our recently-released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization and quality control of biotherapeutic drugs. The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in approximately 200 academic, government, pharmaceutical, and biotech research laboratories worldwide. There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders. The PCT Platform is offered through the Company’s Research Products & Services Group.

The PreEMT Platform can be used to significantly impact and improve the quality of protein therapeutics. It employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies. The PreEMT Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy and safety for both new-drug entities and biosimilar products. The PreEMT Platform can help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. It is scaleable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations. Research and manufacturing licenses are available.

The UST Platform is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. UST has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water. Such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble. We believe that UST has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being developed for commercialization.

1. Shares Outstanding (as August 15, 2018) – includes approximately 1.5M common shares and 5.7M common share equivalents from Preferred Stock Series D, G, H, J, K, and AA on an as-converted basis.
2. Fully Diluted Market Capitalization is calculated using Common Stock OS and Common Equivalent Shares OS on a Fully Diluted basis.

INVESTMENT HIGHLIGHTS

- Seasoned Management Team & Board of Directors
 - Three Novel, Enabling, Patent Protected, Proprietary Pressure-based Platforms
 - Proven Core Technology (Over 300 PCT Systems Installed): Razor/Razorblade Business Model
 - Sales into the Research Market (fast market penetration with minimal approvals required)
 - Increasing Number of 3rd Party Publications from Marquee Laboratories
 - PCT Breaks Through Bottlenecks and Barriers to Enable and Accelerate Scientific Discovery
 - PreEMT Can Impact and Improve Protein Drug Therapeutics
 - UST Offers the Potential to Produce Highly Stable Nanoemulsions, Including in the Food and CBD Markets
 - Significant Multi-Billion Dollar Market Opportunity (~500K Scientists in 80K Labs Worldwide)
-

RECENT & KEY ANNOUNCEMENTS

- **September 13, 2018:** the Company announced the commercial release of the HUB880 Explorer, its newest high pressure instrument that is expected to enhance high pressure processing studies for food safety and quality, as well as guide development of PBI's Ultra Shear Technology Platform.
 - **August 30:** the Company was awarded a key US patent for a novel, high-pressure flow-through microfluidic sample preparation device, which should open the path to the development of automated "hands-free" sample preparation workflows utilizing the Company's patented high-pressure platform technologies.
 - **August 15:** the Company reported Q2 2018 financial results, including the 10th consecutive quarterly increase in products and services revenue, record second quarter total revenue of \$638,800 (18% increase over Q2 2017), increases in instrument sales, consumables and gross margin compared to Q2 2017, and a 24% decrease in operating loss from the same period in 2017.
 - **July 19:** the Company announced it was developing a potential breakthrough processing method - based on their patented Ultra Shear Technology - for high quality, shelf-stable milk and other dairy products that would not require refrigeration or chemical additives.
 - **July 12:** The Ohio State University announced they had been awarded an \$891,000 grant from the USDA to develop – together with PBIO - an innovative manufacturing technology to preserve food and beverages using wholesome, recognizable ingredients, no artificial preservatives and reduced use of heat.
 - **June 12:** the Company announced the conversion an additional \$7.24M of Debt into Equity, making a total of \$13.6M of debt that the Company had converted into equity from mid-May to mid-June 2018.
 - **May 15:** the Company announced the conversion of \$6.39M of debt into equity.
 - **May 15:** the Company reported continued revenue increases for Q1 2018, including an 11% increase in products and services sales, an 8% increase in instrument sales, and an 18% increase in consumable sales YoY.
 - **May 3:** the Company announced receipt of the first contract utilizing the recently acquired high pressure technology from BaroFold, Inc. to evaluate PBI's patented Pre-EMT platform to enhance the manufacturing process and improve the quality of protein therapeutic drug candidates.
 - **April 3:** the Company reported Q4 and FY2017 financial results. Instruments, consumables, products & services and total revenue continued to show double-digit growth. Quarterly revenue has increased eight quarters in a row, on a Y/Y basis. Total revenue has increased four years in a row, on a Y/Y basis.
 - **February 14:** the Company announced a two-year, worldwide co-marketing and distribution agreement with ISS, Inc., a global supplier of high pressure optical cell systems.
 - **December 20, 2017:** the Company announced a significant software upgrade for its flagship Barocycler 2320EXTREME instrument.
 - **December 13:** the Company announced the acquisition of all the assets of BaroFold Corp, and its immediate entry into the Biologics Contract Research Services Sector.
 - **November 14:** the Company reported third quarter 2017 financial results, including record total revenue led by increases in products and services (+21%), consumables (+158%), and grant (+23%) sales.
 - **October 18:** the Company announced a strategic collaboration with Phasex Corporation, to combine PBI's Ultra Shear Technology with Phasex's Supercritical Fluid Processing Method to enable the development of stable, water-soluble nanoemulsions, including CBD-enriched plant oil.
 - **October 2:** the Company announced it was issued two patents on its widely-applicable, high pressure-based Ultra Shear Technology. PBI believes that UST can be used to create or improve a broad range of medical, consumer, and industrial products through the preparation of high quality nanoemulsions and "clean label" food.
 - **September 18:** the Company announced that the Barocycler 2320EXTREME was named a Finalist in the prestigious 2017 R&D 100 Awards. Considered among the most prestigious recognitions of invention and innovation worldwide, the R&D 100 awards identify the top 100 revolutionary technologies of the past year.
 - **June 5:** the Company announced that Dr. Ruedi Aebersold received the prestigious Karger Medal for significant contributions to the development of new bioanalytical methods, and that he discussed PBI's patented PCT platform for sample preparation – a critical step in scientific analysis – during his Medal Lecture
 - **March 1, 2017:** the Company's 2320EXTREME Barocycler received the 2017 N. American Excellence Award for "Best New Instrument for Sample Preparation" by Corporate America News, a leading business publication.
-

BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Mr. Kevin A. Pollack, Esq.
- Mr. Vito Mangiardi
- Dr. Mickey Urdea
- Mr. Richard T. Schumacher

09/14/2018